Michael Schöll Group
Short description
Michael Schöll, PhD, is an Associate Professor in molecular medicine with focus on neuroimaging and a member of the Young Academy of Sweden.
About Michael Schöll group
Neurodegenerative diseases are notoriously difficult to diagnose early and there is still no cure available for dementia disorders such as Alzheimer’s disease (AD). Biomarkers derived from imaging modalities such as positron emission tomography (PET) and magnetic resonance imaging (MRI), as well as biomarkers based on the analysis of cerebrospinal fluid (CSF) or blood, have become immensely important especially for the early identification of individuals who are likely to develop a neurodegenerative disorder, since an established notion is that potentially successful treatments should be deployed as early as possible in the disease process.
This early identification of neuropathological processes using adequate biomarkers currently not only supports reliable clinical diagnoses but also serves the recruitment of suitable candidates for clinical treatment trials, and renders possible the application of these biomarkers as outcome measures in treatment trials.
In particular the recent development of methods to map the accumulation of conformationally faulty forms of proteins and the subsequent synaptic impairment in vivo using PET has profoundly changed the way these processes can be identified at an early, presymptomatic disease stage. The Schöll group is using the most recent developments in molecular imaging by means of PET in combination with other neuroimaging- and fluid-based biomarkers, as well as neuropsychological profiling to develop holistic, validated, and usable tools for such an early identification.
Collaborations
The establishment of the Schöll group was strongly coupled with the recent inauguration of the Imaging- and Intervention Center (Bild- och Interventionscentrum – BoIC) at the Sahlgrenska University Hospital, which for the first time offers resources for research involving molecular imaging modalities in West Sweden.
The group has furthermore established extensive national collaborations with researchers and clinicians at the University of Gothenburg / The Sahlgrenska University Hospital, and with researchers at Lund University, the Karolinska Institute, and Umeå University. Internationally, the group collaborates actively, amongst others, with researchers at the University of California, Berkeley, University College London, Stanford University, and McGill University
Contact Information
Michael Schöll
michael.scholl@neuro.gu.se
Department of Psychiatry and Neurochemistry
Sahlgrenska University Hospital
Blå stråket 15, 3rd floor
Gothenburg, Sweden
Visiting Addresses:
Sahlgrenska University Hospital
MedTech West
Röda Stråket 10B
413 45 Gothenburg
Memory Clinic
Wallinsgatan 6
431 41 Mölndal
Fiona receives a Junior Faculty Award during AD/PD 2023
We would like to congratulate Fiona, who received a Junior Faculty Award during AD/PD 2023. The Organizing Committee of AD/PD™ 2023 recognized the top junior and trainee abstract presenters with Junior Faculty Awards. The Conference was held from March 28th – April 1st, in Gothenburg. There were over 4000 attendees and Fiona was one out of 20 recipients.
AD/PD 2023 in Gothenburg
We are thrilled that between March 28 – April 1, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) will be held in our home town, Gothenburg. We are looking forward to present our latest work from a variety of projects and would like to warmly welcome you to attend our (poster) presentations.
"Välkommen till Göteborg" and hope to see you there!
Alzheimer’s Research UK – Research Conference 2023
The UK’s largest dementia research conference took place between March 14 - 15 in Aberdeen, Scotland. Michael was invited as a speaker and presented his latest work during the ‘Biomarkers: from fluid to function’ session.
The Swedish Alzheimer Association – Seminar
As part of Gothenburg’s 400th anniversary, Alzheimerfonden organized the festival ‘Årsrika Göteborg 400’. The purpose of the festival was to start conversations about different ways of aging, as well as to pay a tribute to life and aging in general. Together with other leading Alzheimer’s disease researchers in Sweden, Michael was invited to host a seminar about dementia and other cognitive diseases associated with aging.
Cars and Scientists
In the new YouTube series 'Cars and Scientists', initiated by Ross Paterson (UCL) and Michael, some of the world's top dementia scientists get interviewed about their fields and acievements, all while driving around in a classic car. The first episodes feature interviews with Professors Bill Jagust, John Hardy, and Kaj Blennow. Make sure to check it out here.
Michael and Alexis attend CTAD 2022
Between November 29 - December 2, the 15th annual Clinical Trials on Alzheimer's Disease (CTAD) conference took place in San Francisco (USA), attended by both Michael and Alexis. Alexis was also invited to present his original work: “Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer’s disease spectrum”, which was very well received. Another highlight also includes the highly anticipated presentation of the lecanemab clinical trial results.
William Jagust, Visiting Professor
Wiliam Jagust is a professor of neuroscience and public health at the Helen Wills Neuroscience Institute, University of California, Berkeley. He is a visiting professor at Sahlgrenska Academy, affiliated with the Schöll group 2018-2022.
Michel Grothe, PhD, Senior Research Associate
Michel Grothe is a senior researcher at the Movement Disorders Group of the Institute of Biomedicine of Seville (IBiS), Spain, who is specialized in multimodal PET/MRI neuroimaging techniques for studying neurodegenerative disease pathology in-vivo. He joined the Schöll group in 2019 as a senior research associate to supervise research projects focused on novel analytic techniques for studying cortical pathologic patterns in multimodal imaging data, with a particular focus on the integration of regional information form amyloid- and tau-sensitive PET scans.
Nicolai Franzmeier, PhD, Research Associate
E-mail
Nicolai Franzmeier is a Junior Research Group Leader at the Institute for Stroke and Dementia Research at the LMU University Hospital in Munich. His research uses multimodal PET and MRI-based neuroimaging to develop mechanistic models of Alzheimer’s disease progression, with a particular focus on tau pathology. He joined the Schöll group as an associated researcher in 2022 to co-supervise research projects on tau-PET and fluid biomarkers in Alzheimer’s disease.
Eva Bringman
Eva Bringman is a registered nurse with long experience of clinical research in both healthcare and pharmaceutical industry. She has been working as research coordinator in the field of dementia research at the Department of Neuroscience and Physiology for several years. Joined the Schöll group January 2018
Johan Rung, PhD
E-mail
Johan Rung has a background in neuropharmacology, with a focus on aspects of dopaminergic signalling. He obtained his PhD from the University of Gothenburg, studying dopaminergic stabilizers for the treatment of schizophrenia. He continued his research in a local spin-off company and as a postdoctoral researcher at Oregon Health & Science University in Portland, Oregon, USA. After returning to Gothenburg, he continued to pursue a career in research administration and joined the lab as a Research Coordinator.
Alexis Moscoso Rial, PhD
Alexis Moscoso is a Researcher at the Molecular Neuroimaging laboratory led by Michael Schöll. He joined Michael Schöll’s lab in 2020 as a post-doctoral fellow. His research has a strong focus on neuroimaging biomarkers, as well as fluid biomarkers, for the diagnosis and prediction of Alzheimer’s disease. His primary objective is to continue conducting biomarker research that is useful and applicable in Alzheimer’s disease therapeutic trials and clinical practice.
Fiona Heeman, PhD
E-mail
Fiona Heeman is a postdoctoral researcher who joined the Schöll lab after completing her PhD at the Amsterdam UMC, VUmc. The topic of her dissertation was quantitative amyloid PET imaging in Alzheimer's disease. Most of her projects focussed on optimal methodology for PET data analysis and kinetic modelling of various amyloid ligands. As part of the Schöll lab, Fiona would like to extend her knowledge regarding imaging and non-imaging biomarkers and get involved in more clinically oriented projects.
Meera Srikrishna, PhD
After successfully completing her PhD under the guidance of Dr. Michael Schöll, Meera continues to be part of the group as a postdoctoral researcher. Her research combines the application of image analysis and deep learning in the automated quantification of neurodegeneration. Currently, she is studying deep-learning-based techniques to derive biomarkers from neuroimaging modalities, especially computed tomography (CT). She works with a team of expert researchers, clinicians and other engineers on the clinical validation of AI-based diagnostic support solutions in brain atrophy assessment. She pursued her Masters degree in biomedical engineering and worked for the National Brain Research Centre, India between in 2015-17.
Peter Young, MSc
Peter Young is a PhD student joining the team from the Bristol Royal Infirmary where he worked as a medical physicist in the imaging department of the hospital. Peter has a background in medical imaging, radiation physics and radiation protection which he used for the optimisation and new development of imaging techniques within both hospital and research environments.
Fredrik Öhman
Fredrik Öhman is a PhD student in Michael Schöll's research group and the Institute of Neuroscience and Physiology, Sahlgrenska Academy. Fredrik will use neuropsychology, neuroimaging and neurochemical biomarkers to validate newly developed methods for detecting cognitive impairment in early stage dementia disorders.
Besides Fredrik’s research work, he is a clinical psychologist at the Sahlgrenska University Hospital memory clinic.
Iris Bosch, MSc
Iris has a master’s degree in Brain and Cognitive Sciences from the University of Amsterdam, the Netherlands. She is particularly interested in the usage of neuroimaging techniques to disentangle the pathology of neurodegenerative diseases such as Alzheimer’s disease. Iris graduated with a joint project from the Alzheimer Center Amsterdam and the Department of Radiology & Nuclear Medicine (Amsterdam UMC), where she investigated the predictive value of tau PET and relative cerebral blood flow for atrophy in Alzheimer’s disease.
At the moment she is working on different projects within the research group, mostly with a focus on neuroimaging.
Jessica Johansson
Jessica is a research assistant, currently finishing her Master’s degree in Clinical Psychology at the University of Gothenburg. Jessica joined Michael Schöll’s group after completing an internship at the memory clinic at Sahlgrenska University Hospital. Within the research group, Jessica is mainly carrying out neuropsychological assessments using various instruments.
Malin Jönsson
At the final year of my Master studies in Biomedical engineering at Chalmers University of Technology, I am now excited to do my Master’s Thesis together with the research group with the aim of developing an automated measurement of the callosal angle on head CT. With a background of a B.Sc. in Biotechnology and a special interest for diagnostic imaging and neuroscience, this will be a very interesting project!
Prithvi Arunachalam
Prithvi Arunachalam is a Master's Thesis student, currently pursuing the Erasmus+ International Master in Innovative Medicine (IMIM) program. His research interests span the field of precision medicine and biomarkers for neurodegenerative diseases. Prithvi joined the Molecular Neuroimaging Lab after completing a research internship at the Nordberg Translational Molecular Imaging Lab at Karolinska Institutet where he worked on a project investigating the association between Amyloid Time and the novel plasma biomarkers for Alzheimer’s Disease (AD). For his current thesis project, he is implementing multimodal neuroimaging and statistical methods to map the temporal course of synaptic AD biomarkers in relation to amyloid and tau pathology.
Anniina Snellman, PhD
E-mail
Anniina Snellman is a postdoctoral researcher working with molecular neuroimaging and fluid biomarker development for neurodegenerative diseases. She obtained her PhD from the University of Turku (Finland), where her work at the Preclinical Imaging Laboratory of Turku PET Centre was focused on PET tracer development and validation using microPET and mouse models of Alzheimer’s disease. Anniina currently holds an Academy of Finland postdoctoral fellowship and works jointly at the Neurochemistry Laboratory of the University of Gothenburg and Neurological Research Group at Turku PET Centre.
Oleksiy Itsenko, PhD
Oleksiy is principal radiochemist and QP at the Sahlgrenska PET radiopharmacy. Among his key interests are fast labelling reactions and process development. Oleksiy received his PhD in 11C radiochemistry working in the research group of professor Bengt Långström. His experience includes the production of PET tracers for preclinical and clinical use as well as industrial product prototyping.
- Marie Eckerström, PhD, Psychologist
- Irena Burmann, PhD, Postdoc
- Kerstin Heurling, PhD, Postdoc
- Antoine Leuzy, Postdoc
- Franziska Mauter, BSc, Master's Student
- Michihiko Koeda, Visiting Researcher, University of Nippon Medical School, Japan
- Dimitra Tzaferou, Research Assistant
- Putu Ayuwidia Ekaputri, MSc, Intern
- Samuel Berkins, MSc, Intern
- Thomas Vogels, PhD, Researcher
- Ambra Dreos, PhD, Postdoc
- Tora Dunås, PhD, Research Assistant
- Jennifer Alvén, PhD
- Emily Jacoby Kask, Psychologist
- Nicholas Ashton, PhD, Senior Researcher
- Sofie Imer, Intern
- Aleksandra Petrovskaia, MSc, Intern
- Kenneth Dahl, Radiochemist
- Li Lin, Associated Researcher
6th Workshop on Biomarkers for neurodegenerative diseases - May 15-19, 2023
This year's edition of the Biomarker course (UCL/UGOT) was hosted by, and organized in collaboration with, the Barcelonaβeta Brain Research Center. The course is a unique opportunity to delve into biomarkers and explore new frontiers of research, and was attended by 60 doctoral students from 11 different countries.
Click here to watch a Catalan news item about the biomarker course, including an interview with Michael.
AD/PD 2023 - March 28-April 1, 2023
This year’s edition of the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) was held in our home town, Gothenburg. It was a great pleasure to welcome fellow researchers from around the world to Gothenburg, to discuss latest findings and to strengthen current, as well as establish new collaborations.
All in all, it was a very interesting, inspiring, and fun AD/PD edition! "Välkommen åter".
WCMTM Yearly Event - March 21, 2023
On the 21st of March, our lab attended the Wallenberg Centre for Molecular and Translational Medicine (WCMTM) yearly event. Different WCMTM researchers presented their work and, with the theme of this years event being 'knitting networks for life science', examples and views on good collaborations within life sciences were shared. Michael also presented our latest study called 'REAL-AD', investigating a realistic screening approach for preclinical Alzheimer's disease. All in all, it was a day filled with interesting talks and inspiring network opportunities!
Christmas dinner - 16 December, 2022
Just before the holidays we got together to enjoy a typical Swedish Christmas buffet, a 'Julbord'. We were welcomed by Långedrag Värdshus, a restaurant located right on the west coast. We had a great night and are looking forward to what 2023 will bring!
NeuroPET meeting 2022 – 4-5 October, 2022
At the beginning of October, our research group traveled to Stockholm to attended NeuroPET 2022, the annual meeting for neuroPET research in Sweden. It was a great pleasure to come together with fellow researchers from all over Sweden, representing the Universities of Gothenburg, Linköping, Lund, Stockholm, Umeå and Uppsala.
Over the course of two days, we discussed latest findings, current work and future goals. We had a great time together and are looking forward to what the future will hold for neuroPET research in Sweden!
The Wallenberg Centre yearly kick-off – 19-20 September, 2022
Being part of The Wallenberg Centre for Molecular and Translational Medicine (WCMTM), our research group got invited to the yearly kick-off event. The event took place at Aspenäs Herrgård and here we got together with all other WCMTM research groups to connect and establish potential collaborations. We had a great time meeting everyone.
AAIC 2022 – July 31-August 4, 2022
This year’s edition of the Alzheimer’s Association International Conference (AAIC) took place in San Diego, USA. We were delighted to be able to attend the conference in person again and come together with researchers from all over the world to advance dementia science.
Our lab was also invited to share our latest work through oral presentations, workshop contributions, and poster presentations during both the main conference, as well as the Alzheimer’s Imaging Consortium (AIC) and Technology & Dementia preconferences.
It was a very interesting, inspiring, and fun AAIC edition!
Summer barbecue - June 22, 2022
As an end of the academic year get-together, we enjoyed a barbecue with the lab. We drank a toast and celebrated this year's accomplishments with burgers and beers. We had a great time!
AD/PD 2022 – March 15-20, 2022
AD/PD 2022 was organised as a hybrid event in Barcelona on March 15-20. Alexis, Michel and Michael were invited to give oral presentations, and the three of them travelled to Barcelona to attend the conference in person.
Alexis presented brand new results from his latest project on 18F-flortaucipir PET visual reads, Michel presented data from his imaging-pathologic association study regarding concomitant lewy body pathology and regional neurodegeneration patterns in Alzheimer’s disease and Michael presented the first results from the Sahlgrenska NeuroCOVID study, as well as an update on ATNG blood biomarkers for Alzheimer’s disease on behalf of Kaj Blennow.
Altogether it was a very interesting, inspiring and fun AD/PD edition!
Lab retreat 2022 – March 7-8, 2022
For this year’s lab retreat, we travelled to Falkenberg Strandbad, a spa hotel on the Swedish west coast. We also had the pleasure of hosting distinguished external collaborators, Dr. Nico Franzmeier from Ludwig Maximilian University of Munich and Institute for Stroke and Dementia Research (Munich), Will Coath from University College London, Dr. Ross Paterson from University College London, and Jörg Hanrieder from University of Gothenburg.
The retreat was kicked off with a delicious lunch, overlooking Skrea Beach. The program then continued with individual presentations. All lab members and external guests presented their research interests, current work, as well as future plans. Altogether it was a great session to get to know each other better, spark ideas for future research and identify potential collaborations. The rest of the afternoon was filled with one of Sweden’s most beloved ways to relax – visiting a spa. The day ended with socializing over yet another delicious meal, drinks and games.
The second day was all about mission and vision. During the first part, we talked about what we do as a group, our mission and what we are striving to achieve. It turned out to be a very meaningful and inspiring conversation and we re-defined the group’s mission and vision. During the second part we zoomed in on our personal profiles and visions and how these could be aligned in a two-way manner with the mission and vision of the group. The retreat was concluded with a team-building game and lunch. We had two wonderful days!
Charity run for the Swedish Brain Foundation – January 15, 2022
On a beautiful morning in January, Meera, Peter and Iris participated in the charity run ‘Hjärnsteget’. The race was initiated by the Swedish Brain Foundation to raise money for research into brain diseases, as well as outreach, this year in particular for epilepsy. We were very happy to join this virtually organised race and support their cause. We are excited to join more races in the future, so stay tuned!
Highlights of previous years
2021 - Summer barbecue
After a long year of working from home, the research group finally had a chance to get together to celebrate this year’s accomplishments with some burgers and beers. The sun was shining, we had a great time, and are now ready to face the rest of the year with renewed energy!
Other group activities this year: Lab dinner, NeuroPET meeting in Umeå, Christmas dinner and PhD course "Biomarkers for neurodegenerative diseases" organized in collaboration with UCL Dementia Research Centre,
2020 - Christmas Dinner
Every year just before the Christmas holidays, our team enjoys a Julbord, a typical Swedish Christmas buffet. This year the traditional Molecular Neuroimaging Julbord was held virtually.
2019 - Molecular Neuroimaging Lab Retreat
Our annual lab retreat was facilitated at Marstrands Havshotell on the 25th-26th of November. We had the pleasure of hosting distinguished external collaborators from universities and research institutions around the world. Our guest list included Dr. David Berron from University of Lund, Sweden, Dr. Andréa Lessa Benedet from McGill Univeristy, Canada, Alexis Moscoso from University of Santiago de Compostela, Spain, as well as Dr. Anne Maass and Dr. Michel Grothe from the German Center for Neurodegenerative Diseases (DZNE).
Other group activities this year: Christmas dinner at Chalmersska Huset
Michael Schöll
- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, Gothenburg, Sweden (2023-04-01): Exploring the basis of COVID-19-related neurological sequelae: 12-month longitudinal data from the Sahlgrenska NeuroCOVID study
- 2nd Swedish Alzheimer Research meeting, Stockholm (2022-04-21): Positron emission tomography in Alzheimer's disease
- Alzheimer’s Association ISTAART Neuroimaging webinar (2021-12-01): Amyloid & Tau PET. Together with Renaud La Joie (PhD), Dave Cash (PhD) and Alexa Pichet Binette (PhD).
- Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-26, Hybrid Conference): The ever-changing landscape of Alzheimer’s disease biomarkers (Featured Research Session). Together with William Jagust (MD, PhD), Melissa Murray (PhD), Thomas Karikari (PhD) and Susan Landau (PhD).
- Mayo Clinic Department of Neuroscience Seminar Series (2021-06-18): A (pretty Swedish) update on biomarkers for tau pathology in Alzheimer’s disease
- Alzheimer’s Association ISTAART Neuroimaging workshop tau PET (2020-10-08
- Genentech, San Francisco (2020-01-13): Biomarkers for tau pathology
- Alzheimer's Association International Conference (AAIC) Los Angeles (2019-07-17): Featured Research Session, Biomarkers for tau pathology. Keynote speakers (Suzanne L. Baker, PhD, Claudia Cicognola, PhD, Anne Maass, PhD, Niklas Mattsson, MD, PhD)
- Human Amyloid Imaging, Miami (2019-01-16): Head-to-head comparison of [18F]Flortaucipir and [18F]RO948 tau PET ligands
- German Centre for Neurodegenerative diseases (DZNE) Magdeburg (2018-12-17): Head-to-head comparison of [18F]Flortaucipir and [18F]RO948 tau PET ligands
- Duke-NUS (2018-11-12): Update on what we believe is tau imaging
- Stanford University (2018-09-03): Update on what we believe is tau imaging
Michel Grothe
- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, Gothenburg, Sweden (2023-04-01): FDG-PET is superior to MRI for tracking neurodegenerative changes associated with early stages of neurofibrillary tangle pathology: An imaging-pathologic association study
Alzheimer’s Association International Conference (AAIC) San Diego, USA (2022-08-01, Hybrid Conference): Differential effects of comorbid Lewy body and Alzheimer’s disease pathology on regional FDG-PET patterns - The 16th International Conference on Alzheimer’s and Parkinson’s Diseases, Barcelona (2022-03-16): Does concomitant Lewy body pathology affect the regional neurodegeneration pattern in Alzheimer’s disease? An imaging-pathologic association study with antemortem FDG-PET
- LATE meeting 2022 (2022-02-10, Virtual Meeting): In-vivo stratification of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC
- Invited presentation at the Selective Vulnerability Research Lab (Seeley Lab), UCSF Memory and Aging Center, University of California, San Francisco, USA (2021-07-01): A neuroimaging perspective on selective regional vulnerability in neurodegenerative disease
- 15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12): Data-driven identification of distinct cognitive subtypes in Parkinson’s disease dementia: Association with clinical, genetic, and biomarker characteristics
- Alzheimer’s Association International Conference (AAIC) 2020, (July 27-31, 2020, Virtual Conference): Disentangling neurodegeneration subtypes of Alzheimer’s disease using data-driven methods (Featured Research Session: Neurobiological subtypes of Alzheimer’s disease).
- Alzheimer’s Association International Conference (AAIC) 2020, (July 27-31, 2020, Virtual Conference): Clinical and neurodegenerative features associated with amyloid-β-negative medial temporal tau deposition as measured by multimodal PET imaging
Alexis Moscoso
- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, Gothenburg, Sweden (2023-04-01): Concordance between visual interpretation and quantitative analysis of [18F]flortaucipir PET images
- 15th Clinical Trials on Alzheimer's Disease (CTAD) conference, San Francisco, USA (2022-11-30): Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum
- Swedish NeuroPET meeting 2022, Stockholm, Sweden (2022-10-04): Prevalence and risk of clinical progression of tau-PET positive individuals across the Alzheimer's disease spectrum
- Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-28, Hybrid Conference): Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation
- 7th Annual Meeting of the European Academy of Neurology (EAN) (2021-06-19)Progression of tau pathology across in-vivo stages of regional amyloid deposition
- The BRAIN Conference (2021-03-04) Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
- 15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12) PET-measured progression of tau pathology across in-vivo stages of regional amyloid deposition
- Alzheimer's Association International Conference (2020): Association of white matter hyperintensities with sub-threshold amyloid accumulation (poster)
- Alzheimer's Association International Conference (2020): Clinical and neurodegenerative features associated with amyloid-β-negative medial temporal tau deposition as measured by multimodal PET imaging (poster)
- Alzheimer's Association International Conference (2020): Evaluation of different partial volume correction methods for longitudinal tau PET imaging (poster)
- Alzheimer's Association International Conference (2020): Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid-β and tau deposition in older individuals without dementia (poster)
Meera Srikrishna
- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, Gothenburg, Sweden (2023-03-29): Evaluating the diagnostic usability of deep-learning-derived CT-based volumetric measures in idipathic normal pressure hydrocephalus
- Hydrocephalus 2022, Gothenburg, Sweden (2022-09-12): Automated quantification of lateral ventricle volumes in normal pressure hydrocephalus from computed tomography scans using deep learning
- Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-27, Hybrid Conference): Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases
- 15th International Conference on Alzheimer’s and Parkinson’s Diseases: Mechanisms, Clinical Strategies and promising Treatments of Neurodegenerative Diseases (2021): First-level assessment of neurodegeneration using deep-learning based brain CT segmentations and blood-derived measures of neurofilament light
- Alzheimer's Association International Conference (2020): T‐based brain segmentation and volumetry using deep learning methods
- SPIE optics and photonics-Emerging topics in Artificial Intelligence 2020 (2020-08-25): Deep learning-based human CT brain segmentation using MRI derived labels
- AAT-ADPD (2020)
Peter Young
- Svensk Förening för Nuklearmedicin (SFNM) (2021-05-19) – Awarded best abstract of the 2021 meeting: Image-derived input functions from dynamic 15O-water PET scans using penalised reconstruction
- British Nuclear Medicine Society (BNMS) spring meeting (2021-05-18): Image-derived input functions from dynamic 15O-water PET scans using penalised reconstruction
- 15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12): Impact of reduced injected dose on the PET quantification of [18F]RO948 to assess tau pathology in vivo
Fredrik Öhman
- Alzheimer's Association International Conference (AAIC) Los Angeles, USA (2019-07): Neuropsychology and 99MTC-HMPAO single photon emission computed tomography findings from the Gothenburg MCI study
Iris Bosch
- Marcus Wallenberg Symposium - Latest advances on medial temporal lobe subregions in cognition, aging, and disease, Lund, Sweden (2022-06-08): Volumetric changes in medial temporal lobe subregions - first results from the Sahlgrenska NeuroCOVID Study
Fiona Heeman
- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, Gothenburg, Sweden (2023-04-01): Relationship between [18F]flortaucipir PET visual patterns and neurodegeneration
- Swedish NeuroPET meeting 2022, Stockholm, Sweden (2022-10-04): Relationship between [18F]flortaucipir PET visual patterns and measures of neurodegeneration
- AMYPAD General Assembly Meeting 2022, Amsterdam, The Netherlands (2022-09-23): Quantification of longitudinal dynamic amyloid PET scans in AMYPAD
Oral presentations:
History and use of FDG PET in Alzheimer’s disease
Michael Schöll
Evaluating the diagnostic usability of deep-learning-derived CT-based volumetric measures in idipathic normal pressure hydrocephalus
Meera Srikrishna, Woosung Seo, Anna Zettergren, Silke Kern, Lars-Olof Wahlund, Eric Westman, Johan Virhammar, David Fällmar, Ingmar Skoog, and Michael Schöll.
REAL AD: A realistic screening approach for preclinical Alzheimer’s disease
Kaj Blennow, Henrik Zetterberg, Silke Kern, and Michael Schöll.
Relationship between [18F]flortaucipir PET visual patterns and neurodegeneration
Fiona Heeman
FDG-PET is superior to MRI for tracking neurodegenerative changes associated with early stages of neurofibrillary tangle pathology: An imaging-pathologic association study
Michel Grothe
Neurobiological and clinical characteristics of amnestic patients with posterior- occipital hypometabolism patterns suggestive of DLB
Jesús Silva-Rodríguez
Exploring the basis of COVID-19-related neurological sequelae: 12-month longitudinal data from the Sahlgrenska NeuroCOVID study
Michael Schöll
Concordance between visual interpretation and quantitative analysis of [18F]flortaucipir PET images
Alexis Moscoso
Posters:
Impact of reduced injected dose on quantitative and qualitative assessment of [18F]flutametamol
Peter Young, Fiona Heeman, Mark Lubberink, Anna Rieckmann, Jan Axelsson, Amir Sanaat, Giovanni Frisoni, Habib Zaidi, Juan Domingo Gispert, Frederik Barkhof, Gill Farrar, Suzanne Baker, Valentina Garibotto, and Michael Schöll.
Volumetric changes in medial temporal lobe subregions and the olfactory bulb of COVID-19 patients – Results from the Sahlgrenska NeuroCOVID study
Iris Bosch, David Berron, Fredrik Öhman, Alexis Moscoso, Hannah Baumeister, Erika Stentoft, Nelly Kanberg, Arvid Edén, Isabella Björkman-Burtscher, Anna Grahn, Magnus Gisslén, and Michael Schöll.
Data-driven approach for feature selection for automated visual tau-PET stratification
Alejandro Costoya-Sánchez, Jesús Silva-Rodríguez, Pablo Aguiar, and Alexis Moscoso.
Oral presentations:
Differential effects of comorbid Lewy body and Alzheimer’s disease pathology on regional FDG-PET patterns
Jesús Silva-Rodríguez, Miguel Labrador-Espinosa, Alexis Moscoso, Michael Schöll, Pablo Mir and Michel J Grothe.
Longitudinal pathologic course of older individuals with medial temporal tau deposition in the absence of amyloid-β pathology
Alejandro Costoya-Sánchez, Alexis Moscoso, Jesús Silva-Rodríguez, Pablo Aguiar, Michael J Pontecorvo, Michael D Devous Sr., Michael Schöll and Michel J Grothe.
Workshops:
Getting Started with Neuroimaging Analysis
David Cash, Ludovica Griffanti, Alexis Moscoso, Tobey Betthauser, Luigi Lorenzini and Alexa Pichet Binette.
Posters:
FDG-PET is a sensitive imaging biomarker of the neurodegenerative changes that accompany early neurofibrillary tangle pathology
Michel Grothe, Jesús Silva-Rodríguez, Alexis Moscoso and Michael Schöll.
Functional brain networks reorganization in the absence of medial temporal lobe structures: an example of neuroplasticity
Cleofé Peña-Gomez, Muge Akinci, Peter Young, Fredrik Öhman, Eleni Palpatzis, Marie Studahl, Eider Arenaza-Urquijo and Michael Schöll.
Impact of Reduced Injected Dose for In Vivo Quantification of Aβ Pathology Using [18f]flutemetamol
Peter Young, Fiona Heeman, Mark Lubberink, Anna Rieckmann, Jan Axelsson, Amirhossein Sanaat, Giovanni Frisoni, Habib Zaidi, Juan Domingo Gispert, Frederik Barkhof, Gill Farrar, Suzanne Baker, Valentina Garibotto and Michael Schöll.
Precision estimates of Relative and Absolute Cerebral Blood Flow in Alzheimer’s disease and Cognitively Normal individuals
Fiona Heeman, Denise Visser, Maqsood Yaqub, Sander Verfaillie, Tessa Timmers, Wiesje van der Flier, Bart van Berckel, Ronald Boellaard, Adriaan Lammertsma and Sandeep Golla.
Prevalence and longitudinal clinical outcomes of negative, moderate, and advanced [18F]flortaucipir PET visual patterns across the Alzheimer's disease spectrum
Alexis Moscoso, Fiona Heeman, Valle Camacho, Martijn van Essen, Michel Grothe, Li Lin, Isminni Mainta, Federica Ribaldi, Michael Devous, Michael Pontecorvo, Giovanni Frisoni, Valentina Garibotto and Michael Schöll.
Relationship between [18F]flortaucipir PET visual patterns and measures of neurodegeneration
Fiona Heeman, Alexis Moscoso, Valle Camacho, Martijn van Essen, Michel Grothe, Li Lin, Isminni Mainta, Federica Ribaldi, Michael Devous, Michael Pontecorvo, Giovanni Frisoni, Valentina Garibotto and Michael Schöll.
Smartphone-based long-term delayed memory performance is associated with the Preclinical Alzheimer's Cognitive Composite and CSF levels of β-amyloid
Fredrik Öhman, David Berron, Johan Skoog, Timothy Hadarsson Bodin, Silke Kern, Anna Zettergren, Kathryn Papp, Henrik Zetterberg, Kaj Blennow, Ingmar Skoog and Michael Schöll.
Oral presentations:
Moscoso A - Prevalence and longitudinal cognitive outcomes of negative, moderate, and advanced 18F-flortaucipir PET visual patterns in aging and Alzheimer’s disease
Grothe MJ - Does concomitant lewy body pathology affect the regional neurodegeneration pattern in Alzheimer’s disease? An imaging-pathologic association study with antemortem FDG-PET
Schöll M – Exploring the basis of COVID-19-related neurological sequelae: First results from the Sahlgrenska NeuroCOVID study
Schöll M – Update on Amyloid, Tau, neurodegeneration and glial (ATNG) blood biomarkers for Alzheimer’s disease (on behalf of professor Kaj Blennow K)
Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation.
Alexis Moscoso, Thomas K Karikari, Michel J Grothe, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow and Michael Schöll.
Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases.
Meera Srikrishna, Nicholas J Ashton, Joana B Pereira, Rolf A Heckemann, Danielle van Westen, Giovanni Volpe, Joel Simrén, Anna Zettergren, Silke Kern, Lars-Olof Wahlund, Bibek Gyanwali, Saima Hilal, Joyce R Chong, Henrik Zetterberg, Kaj Blennow, Eric Westman, Christopher Chen, Ingmar Skoog and Michael Schöll.
Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology.
Michel J Grothe, Alexis Moscoso, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow and Michael Schöll.
Brain Atrophy and White Matter Hyperintensities are Independently Associated with Plasma Neurofilament Light Chain in an Asian Cohort of Patients with Mixed Pathology.
Joyce R Chong, Nicholas J Ashton, Thomas K Karikari, Saima Hilal, Francis Saridin, Tomotaka Tanaka, Michael Schöll, Kaj Blennow, Henrik Zetterberg, Mitchell Kim Peng Lai and Christopher Chen.
Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: biomarkers of synaptic density in Alzheimer’s disease.
Adam P Mecca, Nicholas J Ashton, Ming-Kai Chen, Ryan S O'Dell, Mika Naganawa, Takuya Toyonaga, Wenzhen Zhao, Nabeel B Nabulsi, Ann Brinkmalm, Hlin Kvartsberg, Michael Schöll, Amy F T Arnsten, Yiyun Huang, Kaj Blennow, Henrik Zetterberg, Richard E Carson, Christopher H van Dyck and Johanna Nilsson.
CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: a systematic review and meta-analysis.
Elisa Lancini, Franziska Bart, Lena Haag, Maren Rühling, Nicholas J Ashton, Henrik Zetterberg, Emrah Düzel, Dorothea Hämmerer and Matthew Betts.
CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer’s disease.
Judes Poirier, Nathalie I V Nilsson, Anne Labonté, Pedro Rosa-Neto, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, John Breitner, Sylvia Villeneuve and Cynthia Picard; Prevent-AD Research Group.
Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study.
Juan Domingo Gispert, Isadora Lopes Alves, Katherine R Gray, Christopher Buckley, Lyduine E Collij, Fiona Heeman, Gemma Salvadó, David Vállez García, Peter Connelly, Claire Boutoleau-Bretonnière, Florence Pasquier, Julien Dumurgier, Audrey Gabelle, Bruno Dubois, Pierre Payoux, Oriol Grau-Rivera, Pablo Martinez-Lage, Mercè Boada, Marta Marquié, Rik Vandenberghe, Bernard J Hanseeuw, Miia Kivipelto, Michael Schöll, Philip Scheltens, Giovanni B Frisoni, Craig W Ritchie, Bruno Vellas, Andrew W Stephens, Lisa Ford, Jose Molinuevo, Pieter Jelle Visser,Gill Farrar, Frederik Barkhof; AMYPAD Consortium.
Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers.
Shorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, Erik Stomrud, Inge M W Verberk, Henrik Zetterberg, Nicholas J Ashton, Niklas Mattsson-Carlgren, Pedro Pesini, Leticia Sarasa, Jose A Allué, Charlotte E Teunissen, Jeffrey L Dage, Kaj Blennow and Oskar Hansson.
Disentangling Disease Heterogeneity from Neuroimaging Data via Adaptive Distribution Modeling Based Collaborative Clustering.
Hangfan Liu, Michel J Grothe, Tanweer Rashid, Miguel Labrador-Espinosa, Jon B Toledo and Mohamad Habes.
Distinctive effect of biological sex in AD-related CSF and plasma biomarkers.
Marta Milà-Alomà, Ann Brinkmalm, Juan Lantero Rodriguez, Thomas K Karikari, Nicholas J Ashton, Hlin Kvartsberg, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sánchez-Benavides, Eider M Arenaza-Urquijo, Anna Brugulat-Serrat, Muge Akinci, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Ivonne Suridjan, Gwendlyn Kollmorgen, Erik Stoops, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Jose Molinuevo and Marc Suarez-Calvet; the ALFA study.
Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: an EEG-fMRI study.
Roberta Lizio, Susanna Lopez, Harald Hampel, Patrizia Andrea Chiesa, Claudio Del Percio, Giuseppe Noce, Stefan J Teipel, Gabriel González-Escamilla, Hovagim Bakardjian, Enrica Cavedo, Simone Lista, Andrea Vergallo, Pablo Lemercier, Giuseppe Spinelli, Michel J Grothe, Marie-Claude Potier, Fabrizio Stocchi, Raffaele Ferri, Marie-Odile Habert, Bruno Dubois and Claudio Babiloni; INSIGHT-preAD study group.
Impact of reduced injected dose on the quantification of [18F]RO948 and [18F]Flortaucipir PET for in vivo tau pathology.
Peter Young, Wesley P Thomas, Jan Axelsson, Jakob Himmelmann, Pablo Aguilar Dominguez, Tomas Ohlsson, Oskar Hansson, Mark Lubberink, Sandra Sanabria Bohorquez, Anna Rieckmann, Suzanne L Baker and Michael Schöll.
In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE study.
Fedor Levin, Michel J Grothe, Martin Dyrba, Henning Boecker, Marcel Daamen, Catharina Lange, Katharina Buerger, Michael T Heneka, Christoph Laske, Oliver Peters, Josef Priller, Alfredo Ramirez, Anja Schneider, Annika Spottke, Michael Wagner, Emrah Düzel, Frank Jessen and Stefan J Teipel; the DELCODE study group.
Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer’s disease patients.
Laia Montoliu-Gaya, Nicholas J Ashton, Andréa Lessa Benedet, Juan Lantero Rodriguez, Gunnar Brinkmalm, Thomas K Karikari, Silke Kern, Pedro Rosa-Neto, Henrik Zetterberg, Kaj Blennow and Johan Gobom.
Microglial activation and tau propagate jointly across Braak stages.
Tharick A Pascoal, Andréa Lessa Benedet, Nicholas J Ashton, Min Su Kang, Joseph Therriault, Mira Chamoun, Firoza Z Lussier, Cécile Tissot, Julie Ottoy, Sulanta Mathotaarachchi, Jenna Stevenson, Gassan Massarweh, Michael Schöll, Jean-Paul Soucy, Kaj Blennow, Henrik Zetterberg, Serge Gauthier and Pedro Rosa-Neto.
Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up.
Nelly Kanberg, Joel Simrén, Arvid Éden, Lars-Magnus Andersson, Staffan Nilsson, Nicholas J Ashton, Pär-Daniel Sundvall, Bengt Nellgård, Kaj Blennow, Henrik Zetterberg and Magnus Gisslén.
Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year olds.
Anna Dittrich, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Anna Zettergren, Joel Simrén, Michael Schöll, Eric Westman, Ingmar Skoog and Silke Kern.
Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients.
Michelle Gerards, Ann-Katrin Schild, Dix U Meiberth, Ayda Rostamzadeh, Jörg Janne Vehreschild, Sebastian Wingen-Heimann, Pamela V Martino Adami, Oezguer A Onur, Alfredo Ramirez, Thomas K Karikari, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Franziska Maier and Frank Jessen.
Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer’s disease.
Daniel Alcolea, Constance Delaby, Laia Muñoz, Soraya Torres, Teresa Estellés, Nuole Zhu, Isabel Barroeta, Maria Carmona-Iragui, Ignacio Illán-Gala, Miguel A Santos-Santos, Miren Altuna, Isabel Sala, Belen Sánchez-Saudinós, Laura Videla, Sílvia Valldeneu, Andrea Subirana, Jordi Pegueroles, Christophe Hirtz, Jérôme Vialaret, Sylvain Lehmann, Thomas K Karikari, Nicholas J Ashton, Kaj Blennow, Henrik Zetterberg, Olivia Belbin, Rafael Blesa, Jordi Clarimón, Juan Fortea and Alberto Lleó.
Plasma glial fibrillary acidic protein is an early and specific marker of amyloid-β pathology in Alzheimer’s disease.
Joana B Pereira, Shorena Janelidze, Ruben Smith, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Henrik Zetterberg, Erik Stomrud, Nicholas J Ashton, Kaj Blennow and Oskar Hansson.
Plasma P-tau181 and NfL are central nodes in a network of diagnostic, biomarker, and demographic data.
Brandon E Frank, Madeline Ally, Bailee Brekke, Henrik Zetterberg, Kaj Blennow, Michael Sugarman, Nicholas J Ashton, Thomas K Karikari, Yorghos Tripodis, Ann C McKee, Thor D Stein, Brett M Martin, Joseph Palmisano, Eric Steinberg, Irene Simkin, Katherine W Turk, Andrew Budson, Maureen K O'Connor, Rhoda Au, Wendy Qiu, Lee E Goldstein, Ronald J Killiany, Neil W Kowall, Jesse Mez, Robert A Stern and Michael L Alosco.
Plasma p-Tau181 and p-Tau231 offer complementary information to identify Alzheimer's disease pathophysiology.
Pamela C L Ferreira, Wagner Scheeren Brum, João Pedro Ferrari-Souza, Cécile Tissot, Bruna Bellaver, Joseph Therriault, Andréa Lessa Benedet, Nicholas J Ashton, Stijn Servaes, Firoza Z Lussier, Mira Chamoun, Jenna Stevenson, Nesrine Rahmouni, Serge Gauthier, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Eduardo R Zimmer, Thomas K Karikari, Pedro Rosa-Neto and Tharick A Pascoal.
Plasma p-tau231 in the Alzheimer’s disease continuum: a multi-cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application.
Nicholas J Ashton, Thomas K Karikari, Juan Lantero Rodriguez, Andréa Lessa Benedet, Anniina Snellman, Tharick A Pascoal, Serge Gauthier, Pedro Rosa-Neto, Clifford R Jack Jr., Ronald C Petersen, Michelle M Mielke, Pratishtha Chatterjee, Ralph N Martins, Madhav Thambisetty, Vijay R Varma, Susan M Resnick, Nick C Fox, Antoinette O'Connor, Agathe Vrillon, Claire Paquet, Sylvia Villeneuve, Judes Poirier, Prevent-AD Research Group, Doug R Galasko, Marta Milà-Alomà, Carolina Minguillón, Karine Fauria, Marc Suarez-Calvet, Eugeen Vanmechelen, Henrik Zetterberg and Kaj Blennow.
Tau pathology progression across PET-based stages of regional amyloid deposition.
Alexis Moscoso, Michel J Grothe and Michael Schöll.
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum.
Joel Simrén, Andréa Lessa Benedet, Nicholas J Ashton, Tharick A Pascoal, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow.
The association of Alzheimer’s disease and cerebrovascular disease biomarkers towards the neurodegeneration of the cholinergic pathways.
Nira Cedres, Daniel Ferreira, Milan Nemy, Alejandra Machado, Joana B Pereira, Lars-Olof Wahlund, Anna Zettergren, Stefan J Teipel, Michel J Grothe, Maria Eriksdotter, Olga Stepankova, Lenka Vyslouzilova, Kaj Blennow, Henrik Zetterberg, Silke Kern, Ingmar Skoog and Eric Westman.
When is a biomarker an AD biomarker? – Face versus construct validity and practical implications for differential application.
Michael Schöll.
Oral presentations:
Nicholas J. Ashton – Novel plasma p-tau231 in Alzheimer’s disease: Early increase indicates utility for preventive trial selection
Alexis Moscoso – PET-measured progression of tau pathology across in-vivo stages of regional amyloid deposition
Peter Young – Impact of reduced injected dose on the pet quantification of [18F]RO948 to assess tau pathology in vivo
Thomas Vogels – AAV vectors to study the functional consequences of neuronal and astrocytic tau pathology using in vivo 2-photon imaging
Meera Srikrishna – First-level assessment of neurodegeneration using deep-learning based brain CT segmentations and blood-derived measures of neurofilament light
Michel J. Grothe – Data-driven identification of distinct cognitive subtypes in Parkinson’s disease dementia: Associations with clinical, genetic, and biomarker characteristics
Anniina Snellman – Novel total tau assays: Exploring tau fragments in alzheimer’s disease and other neurological disorders
Posters:
Neuropathologic correlates of elecsys-derived cerebrospinal fluid biomarkers of Alzheimer’s disease in comparison to a novel plasma-based p-tau181 biomarker
M. Grothe, N. Ashton, A. Moscoso, H. Zetterberg, K. Blennow, M. Schöll
Association of blood phosphorylated tau181 and neurofilament light with progressive neurodegeneration in Alzheimer disease
A. Moscoso, M. Grothe, N. Ashton, H. Zetterberg, K. Blennow, M. Schöll
Simultaneous measurement of site-specific tau phosphorylations in blood for early and accurate diagnosis of Alzheimer´s disease
L. Montoliu-Gaya, N. Ashton, M. Sauer, J. Lantero Rodriguez, G. Brinkmalm, T. Karikari, S. Kern, H. Zetterberg, K. Blennow, J. Gobom
Plasma inflammatory and neurodegeneration markers and disease progression in Lewy bodies disorders
A. Pilotto, A. Imarisio, E. Garraffa, F. Conforti, A. Scalvini, S. Masciocchi, S. Nocivelli, R. Turrone, S. Gipponi, E. Cottina, B. Borroni, M. Rizzetti, M. Pizzi, A. Bellucci, L. Bonanni, H. Zetterberg, N. Ashton, A. Hye, A. Padovani
Alternative protocols to support blood collection in challenging pre-analytical conditions
J. Simrén, K. Blennow, H. Zetterberg, N. Ashton
Cognitive impairment in PSP relates to degeneration of the nucleus basalis of Meynert
S. Rogozinski, G. Respondek, M. Grothe, J.B. Pereira, G. Höglinger
Poster- Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid-β and tau deposition in older individuals without dementia.
Michel J. Grothe, Gemma Salvadó, Colin Groot, Alexis Moscoso, Juan Domingo Gispert, Michael Schöll and Rik Ossenkoppele.
Poster- Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease.
Joyce R Chong, Kaj Blennow, Henrik Zetterberg, Michael Schöll, Nicholas J Ashton, Thomas K Karikari, Francis Saridin, Tomotaka Tanaka, Saima Hilal, Mitchell Kim Peng Lai and Christopher Chen.
Poster- Plasma-based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease.
Antoine Leuzy, Nicholas J Ashton, Thomas K Karikari, Joel Simrén, Gustav Mårtensson, Andréa Lessa Benedet, Abdul Hye, Michael Schöll, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kłoszewska, Simon Lovestone, Dag Aarsland, Niklas Mattsson, Oskar Hansson, Eric Westman, Kaj Blennow and Henrik Zetterberg.
Poster- Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study.
Isadora Lopes Alves, Juan Domingo Gispert, Katherine R Gray, Lyduine Collij, Fiona Heeman, Gemma Salvadó, Laure Saint-Aubert, Pierre Payoux, Bruno Vellas, Claire Boutoleau-Bretonnière, Audrey Gabelle, Florence Pasquier, Julien Dumurgier, Bruno Dubois, Peter Connelly, Oriol Grau-Rivera, Pablo Martinez-Lage, Mercè Boada, Marta Marquie, Rik Vandenberghe, Bernard Hanseeuw, Miia Kivipelto, Michael Schöll, Giovanni B Frisoni, Philip Scheltens, Craig W. Ritchie, Andrew W Stephens, Christopher Buckley, Lisa Ford, Jose Luis Molinuevo, Gill Farrar and Frederik Barkhof.
Poster- CT-based brain segmentation and volumetry using deep learning methods.
Meera Srikrishna, Joana B Pereira, Rolf A Heckemann, Giovanni Volpe, Anna Zettergren, Silke Kern, Eric Westman, Ingmar Skoog and Michael Schöll.
Poster- Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.
Alexis Moscoso, A.J. Whitman, Suzanne L. Baker, Renaud La Joie, Tharick A. Pascoal, Pedro Rosa-Neto, Gil D. Rabinovici, William J. Jagust, Michel Grothe and Michael Schöll.
SCR2-09-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology.
Nicholas J Ashton, Andréa Lessa Benedet, Tharick A. Pascoal , Hlin Kvartsberg, Thomas K Karikari, Michael Schöll, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Mira Chamoun, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow
Poster- Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease.
Adam P. Mecca, Nicholas J Ashton, Ming-Kai Chen, Ryan S. O'Dell, Mika Naganawa, Takuya Toyonaga,; Joanna E. Harris, Hugh H. Bartlett, Emmie R. Banks, Victoria L. Kominek, Nabeel B. Nabulsi, Soheila Najafzadeh, Brent C. Vander Wyk, Ann Brinkmalm, Hlin Kvartsberg, Michael Schöll, Amy F. T. Arnsten, Yiyun Huang, Kaj Blennow, Henrik Zetterberg, Richard E. Carson and Christopher H. van Dyck.
Poster- Clinical and neurodegenerative features associated with amyloid-β-negative medial temporal tau deposition as measured by multimodal PET imaging.
Michel J. Grothe, Alexis Moscoso and Michael Schöll.
Poster- Association of white matter hyperintensities with sub-threshold amyloid accumulation.
Alexis Moscoso, David Rey-Bretal, Jesús Silva-Rodríguez, Michel Grothe, Michael Schöll and Pablo Aguiar.
ODO2-04-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology.
Nicholas J Ashton, Andréa Lessa Benedet, Tharick A. Pascoal , Hlin Kvartsberg, Thomas K Karikari, Michael Schöll, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Mira Chamoun, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow.
Poster- Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET.
David M Cash, Pawel J Markiewicz, Jieqing Jiao, William Coath, Marc Modat, Christopher A Lane, Thomas D Parker, Sarah E Keuss, Sarah M Buchanan, Ninon Burgos, John Dickson, Anna Barnes, Jorge Cardoso, Isadora Lopes Alves, Frederik Barkhof, David L Thomas, Daniel Beasley, Andrew Wong, Michael Schöll, Marcus Richards, Sebastien Ourselin, Nick C Fox and Jonathan M Schott
Poster- Plasma-based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease.
Antoine Leuzy, Nicholas J Ashton, Thomas K Karikari, Joel Simrén, Gustav Mårtensson, Andréa Lessa Benedet, Abdul Hye, Michael Schöll, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kłoszewska, Simon Lovestone, Dag Aarsland, Niklas Mattsson, Oskar Hansson, Eric Westman, Kaj Blennow and Henrik Zetterberg.
SCR2-09-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology.
Nicholas J Ashton, Andréa Lessa Benedet, Tharick A. Pascoal , Hlin Kvartsberg, Thomas K Karikari, Michael Schöll, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Mira Chamoun, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow.
Poster- Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard.
Joel Simrén, Antoine Leuzy, Thomas K Karikari, Abdul Hye, Niklas Mattsson, Oskar Hansson, Michael Schöll, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Hilkka Soininen, Simon Lovestone, Dag Aarsland, Eric Westman, Kaj Blennow, Henrik Zetterberg, Nicholas J Ashton.
Poster- Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET.
David M Cash, Pawel J Markiewicz, Jieqing Jiao, William Coath, Marc Modat, Christopher A Lane, Thomas D Parker, Sarah E Keuss, Sarah M Buchanan, Ninon Burgos, John Dickson, Anna Barnes, Jorge Cardoso, Isadora Lopes Alves, Frederik Barkhof, David L Thomas, Daniel Beasley, Andrew Wong, Michael Schöll, Marcus Richards, Sebastien Ourselin, Nick C Fox and Jonathan M Schott.
Poster- Amyloid-β, tau, synaptic, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer’s continuum.
Marc Suárez-Calvet, Marta Milà-Alomà, Gemma Salvadó, Juan Domingo Gispert, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sanchez-Benavides, Eider M Arenaza-Urquijo, Marta Crous-Bou, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Maryline Simon, Gwen Kollmorgen, Juan Rodríguez-Lantero11,12; Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo.
SCR2-01-04 The effect of physical activity on CSF biomarkers of Alzheimer’s disease differs between men and women.
Marta Milà-Alomà, Gemma Salvadó, Juan Domingo Gispert, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sanchez-Benavides, Eider M Arenaza-Urquijo, Marta Crous-Bou, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Maryline Simon, Gwendlyn Kollmorgen, Juan Rodríguez-Lantero, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo and Marc Suárez-Calvet.
Poster- Serum NfL as a predictor of disease progression in Dementia with Lewy bodies.
Andrea Pilotto, Alberto Imarisio, Francesca Conforti, Alessandro Lupini, Giuliana Giannì, Stefano Gipponi, Elisabetta Cottini, Stefano Masciocchi, Sara Nocivelli, Roberto Grasso, Rosanna Turrone, Barbara Borroni, Maria Cristina Rizzetti, Laura Bonanni, Marina Pizzi, Arianna Bellucci, Emirena Garrafa, Henrik Zetterberg, Abdul Hye, Nicholas J Ashton and Alessandro Padovani.
Poster- CSF phosphorylated tau-217 is increased in Alzheimer’s and Creutzfeldt-Jakob diseases, and correlates with amyloid pathology.
Andreja Emeršič, Thomas K Karikari, Juan Rodríguez-Lantero, Nicholas J Ashton, Uros Rot, Milica G Kramberger, Saša Čučnik, Henrik Zetterberg and Kaj Blennow.
SFRS2-01-03 Alzheimer’s Disease Biomarker Roadmap 2020: second-generation tau PET tracers.
Gerard N Bischof, Alessandra Dodich, Nicholas J Ashton, Marina Boccardi, Henryk Barthel, Maria C. Carrillo, Konstantinos Chiotis, Julie Corre, Jean-François Démonet, Anton F. Gietl, Keith A. Johnson, Oskar Hansson, Antoine Leuzy, Marco Lorenzi, Agneta K Nordberg, Rik Ossenkoppele, Gil D. Rabinovici, Osman Ratib, Osama Sabri, Valerie Treyer, Paul G. Unschuld, Victor L L Villemagne, Emma E. Wolters, Bengt Winblad, Giovanni B. Frisoni, Valentina Garibotto and Alexander Drzezga.
SFRS2-01-04 Alzheimer’s Disease Biomarker Roadmap 2020: fluids biomarkers.
Nicholas J Ashton, Antoine Leuzy, Thomas K Karikari, Alessandra Dodich, Marina Boccardi, Henryk Barthel, Gerard N Bischof, Maria C. Carrillo, Konstantinos Chiotis et al.
ODO2-01-04 The effect of physical activity on CSF biomarkers of Alzheimer’s disease differs between men and women.
Marta Milà-Alomà, Gemma Salvadó, Juan Domingo Gispert, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sanchez-Benavides, Eider M Arenaza-Urquijo, Marta Crous-Bou, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Maryline Simon, Gwendlyn Kollmorgen, Juan Rodríguez-Lantero, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo and Marc Suárez-Calvet.
SFRS2-01-01 Alzheimer’s Disease Biomarker Roadmap 2020: time for tau.
Alessandra Dodich, Marina Boccardi, Nicholas J Ashton, Henryk Barthel, Gerard N Bischof, Maria C. Carrillo, Konstantinos Chiotis et al.
Poster- Identification of Plasma Proteome Signatures Associated with ATN framework Using SOMAscan.
Liu Shi, Sarah Westwood, Alison L Baird, Noel Buckley, Valerija Dobricic, Fabian Kilpert, Shengjun Hong, Andreas Franke, Abdul Hye, Nicholas J Ashton et al.
SO2-03-02 Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
Juan Lantero Rodriguez, Thomas K Karikari, Marc Suárez-Calvet, Claire Troakes, Andrew King, Andreja Emeršič, Dag Aarsland, Abdul Hye, Henrik Zetterberg, Kaj Blennow and Nicholas J Ashton.
SFRS2-01-02 Alzheimer’s Disease Biomarker Roadmap 2020: [18F]flortaucipir.
Emma E. Wolters, Konstantinos Chiotis, Alessandra Dodich, Nicholas J Ashton, Henryk Barthel, Gerard N Bischof, Marina Boccardi, Maria C. Carrillo, Julie Corre, Jean-François Démonet, Alexander Drzezga, Anton F. Gietl, Oskar Hansson, Keith A. Johnson, Antoine Leuzy, Marco Lorenzi, Gil D. Rabinovici, Osman Ratib, Osama Sabri, Valerie Treyer, Paul G. Unschuld, Victor L L Villemagne, Bengt Winblad, Giovanni B. Frisoni, Valentina Garibotto, Agneta K Nordberg and Rik Ossenkoppele.
SO2-01-03 Microglial activation indexed by [11C]PBR28 is associated with synaptic depletion in the Alzheimer’s disease spectrum.
Andréa Lessa Benedet, Nicholas J Ashton, Tharick A. Pascoal , Ann Brinkmalm, Johanna Nilsson, Hlin Kvartsberg, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Cécile Tissot, Mira Chamoun, Kaj Blennow, MD, Henrik Zetterberg and Pedro Rosa-Neto.
SO2-01-06 SNAP25 reflects amyloid- and tau-related synaptic damage: associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimer’s disease spectrum.
Andréa Lessa Benedet, Nicholas J Ashton, Tharick A. Pascoal ,Ann Brinkmalm, Johanna Nilsson, Hlin Kvartsberg, Sulantha Mathotaarachchi, Mélissa Savard, Joseph Therriault, Cécile Tissot, Mira Chamoun, Henrik Zetterberg, Kaj Blennow and Pedro Rosa-Neto.
Poster- Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls
Hlin Kvartsberg, Jozef Hanes, Andréa Lessa Benedet, Nicholas J Ashton, Tharick A. Pascoal, Pedro Rosa-Neto, Oskar Hansson, Henrik Zetterberg, Norbert Zilka and Kaj Blennow.
Current funding
- (Knut and Alice Wallenberg Foundation) Wallenberg Centre for Molecular and Translational Medicine
- The Swedish Research Council
- The Swedish Alzheimer Foundation
- SciLifeLab National COVID-19 Research Program funded by Knut and Alice Wallenberg Foundation
- The Swedish Brain Foundation
- Wilhelm and Martina Lundgren Science Fund
- Sahlgrenska Academy
- ALF Västra Götaland Region
- The Association FTD
- FORTE
- Björnsson Foundation
- Magnus Bergvall Foundation
- ARUK Pump award
Awards
- Birger Karlsson Science Award (Royal Society of Arts and Sciences in Gothenburg)
- Queen Silvia Prize to a Young Alzheimers Researcher (Swedish Alzheimer Association, 2018)
- Best oral presentation (Alzheimer's Association)
- Full conference award (Alzheimer's Association)
- Best abstract and presentation (Swedish Brain Power)
GRANTS
Alexis Moscoso
- Stiftelsen för Gamla Tjänarinnor
- Alzheimer's Association Research Fellowship
Fredrik Öhman
- Anna-Lisa and Bror Björnsson Foundation
- The Handlanden Hjalmar Svensson Foundation
- Gun and Bertil Stohne Foundation
- Fredrik and Ingrid Thuring Foundation
- Sahlgrenska Academy's Travel Grant
- Swedish Association of Neuropsychologists
Meera Srikrishna
- Gun and Bertil Stohne Foundation
- Stiftelsen för Gamla Tjänarinnor
- The Sisters Greta Johansson and Brita Anderssons Memorial Foundation
- Anna-Lisa and Bror Björnsson Foundation
Peter Young
- Anna-Lisa and Bror Björnsson Foundation
- NMMP Facilitation Grant
- GU Travel Grant
- Gun and Bertil Stohne Foundation
Fiona Heeman
- Alzheimer's Association Research Fellowship
- Gun and Bertil Stohne Foundation
AWARDS
Fredrik Öhman
- Carin Mannheimer award for junior scientists (2020)
Meera Srikrishna
- Honorary Mention for the Carin Mannheimer Award (2021)
Peter Young
- Award for best abstract of the Svensk Förening för Nuklearmedicin (SFNM), 2021 meeting
Fiona Heeman
- AD/PD 2023 Junior Faculty Award
Dissertations
Meera Shrikrishna, 2022
Deriving biomarkers from computed tomography using deep learning
Antoinette O'Connor, 2021
Familial Alzheimer’s disease: preclinical disease and pathophysiology biomarkers
Axel Tjörnstrand, 2020
Pituitary tumors - epidemiology and the diagnostic value of 68 Ga-DOTATOC PET/CT
Jennifer Alvén, 2020
Combining Shape and Learning for Medical Image Analysis-Robust, Scalable and Generalizable Registration and Segmentation
Publications (WCMTM Affiliation)
For a full list of Michael Schöll’s publications, please refer to Google Scholar
https://scholar.google.com/citations?user=hEHgZxMAAAAJ&hl=de
Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study.
Visser D, Verfaillie SCJ, Bosch I, Brouwer I, Tuncel H, Coomans EM, Rikken RM, Mastenbroek SE, Golla SSV, Barkhof F, van de Giessen E, van Berckel BNM, van der Flier WM, Ossenkoppele R.
Eur J Nucl Med Mol Imaging. 2023 Mar 28.
DOI: https://doi.org/10.1007/s00259-023-06196-2. Online ahead of print.
Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease.
Chong JR, Hilal S, Ashton NJ, Karikari TK, Reilhac A, Vrooman H, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP.
Alzheimer’s Dement. 2023 Mar 26.
DOI: https://doi.org/10.1002/dad2.12396.
Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
Coomans EM, Tomassen J, Ossenkoppele R, Tijms BM, Lorenzini L, Ten Kate M, Collij LE, Heeman F, Rikken RM, van der Landen SM, den Hollander ME, Golla SSV, Yaqub M, Windhorst AD, Barkhof F, Scheltens P, de Geus EJC, Visser PJ, van Berckel BNM, den Braber A.
Brain. 2023 Mar 9.
DOI: https://doi.org/10.1093/brain/awad077. Online ahead of print.
Image-derived input functions from dynamic 15O-water PET scans using penalised reconstruction.
Young P, Appel L, Tolf A, Kosmidis S, Burman J, Rieckmann A, Schöll M, Lubberink M.
EJNMMI Phys. 2023 Mar 7; 10(1):15.
DOI: https://doi.org/10.1186/s40658-023-00535-w.
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact.
Collij LE, Farrar G, Valléz García D, Bader I, Shekari M, Lorenzini L, Pemberton H, Altomare D, Pla S, Loor M, Markiewicz P, Yaqub M, Buckley C, Frisoni GB, Nordberg A, Payoux P, Stephens A, Gismondi R, Visser PJ, Ford L, Schmidt M, Birck C, Georges J, Mett A, Walker Z, Boada M, Drzezga A, Vandenberghe R, Hanseeuw B, Jessen F, Schöll M, Ritchie C, Lopes Alves I, Gispert JD, Barkhof F. Front Neurol. 2023 Jan 20; 13:1063598.
DOI: https://doi.org/10.3389/fneur.2022.1063598.
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Caprioglio C, Ribaldi F, Visser LNC, Minguillon C, Collij LE, Grau-Rivera O, Zeyen P, Molinuevo JL, Gispert JD, Garibotto V, Moro C, Walker Z, Edison P, Demonet JF, Barkhof F, Scheltens P, Alves IL, Gismondi R, Farrar G, Stephens AW, Jessen F, Frisoni GB, Altomare D; AMYPAD consortium.
JAMA Netw Open. 2023 Jan 3; 6(1):e2250921.
DOI: https://doi.org/10.1001/jamanetworkopen.2022.50921.
Oxidation-Cyclisation of Biphenyl Thioethers to Dibenzothiophenium Salts for Ultrarapid 18F-Labelling of PET Tracers.
Sirindil F, Maher S, Schöll M, Sander K, Årstad E.
International Journal of Molecular Sciences. 2022 Dec 7; 23(24):15481
DOI: https://doi.org/10.3390/ijms232415481.
Unsupervised mobile app-based cognitive testing in a population-based study of older adults born 1944.
Öhman F, Berron D, Papp K V, Kern S, Skoog J, Hadarsson Bodin T, Zettergren A, Skoog I, Schöll M.
Frontiers in Digital Health. 2022 Nov 8.
DOI: https://doi.org/10.3389/fdgth.2022.933265. Online ahead of print.
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, Otero Svaldi D, Higgins IA, Pontecorvo M, Römer S, Steward A, Rubinski A, Zheng L, Schöll M, Shcherbinin S, Ewers M, Franzmeier N; Alzheimer’s Disease Neuroimaging Initiative.
lzheimers Res Ther. 2022 Nov 7; 14(1):166.
DOI: https://doi.org/10.1186/s13195-022-01105-5.
Good manufacturing procedure production of [18F]SynVesT-1, a radioligand for in vivo positron emission tomography imaging of synaptic vesicle glycoprotein 2A.
Dahl K, Larsson S, Bonn P, Wallin A, Itsenko O, Schöll M.
J Labelled Comp Radiopharm. 2022 Aug 31.
DOI: https://doi.org/10.1002/jlcr.4002. Online ahead of print.
Differential effects of tau stage, Lewy body pathology, and substantia nigra degeneration on FDG-PET patterns in clinical AD.
Silva-Rodriguez J, Labrador-Espinosa MA, Moscoso A, Scholl M, Mir P, Grothe M.
J Nucl Med. 2022 Aug 25.
DOI: https://doi.org/10.2967/jnumed.122.264213. Online ahead of print.
Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC.
Grothe MJ, Moscoso A, Silva-Rodríguez J, Lange C, Nho K, Saykin AJ, Nelson PT, Schöll M, Buchert R, Teipel S; Alzheimer's Disease Neuroimaging Initiative.
Alzheimers Dement. 2022 Aug 15.
DOI: https://doi.org/10.1002/alz.12763. Online ahead of print.
Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.
Cedres N, Ferreira D, Nemy M, Machado A, Pereira JB, Shams S, Wahlund LO, Zettergren A, Stepankova O, Vyslouzilova L, Eriksdotter M, Teipel S, Grothe MJ, Blennow K, Zetterberg H, Schöll M, Kern S, Skoog I, Westman E.
Neurology. 2022 Aug 2.
DOI: https://doi.org/10.1212/WNL.0000000000200930. Online ahead of print.
Impact of spill-in counts from off-target regions on [18F]Flortaucipir PET quantification.
López-González FJ, Costoya-Sánchez A, Paredes-Pacheco J, Moscoso A, Silva-Rodríguez J, Aguiar P; Alzheimer’s Disease Neuroimaging Initiative.
Neuroimage. 2022 Jun 24; 259.
DOI: https://doi.org/10.1016/j.neuroimage.2022.119396. Online ahead of print.
Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies.
Moscoso A, Wren MC, Lashley T, Arstad E, Murray ME, Fox NC, Sander K, Schöll M.
Mol Neurodegener. 2022 Jun 3; 17(1): 39.
DOI: https://doi.org/10.1186/s13024-022-00543-x
Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.
Shahim P, Zetterberg H, Simren J, Ashton NJ, Norato G, Schöll M, Tegner Y, Diaz-Arrastia R, Blennow K.
Neurology. 2022 Jun 2.
DOI: https://doi.org/10.1212/WNL.0000000000200615 Online ahead of print.
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
Edén A, Grahn A, Bremell D, Aghvanyan A, Bathala P, Fuchs D, Gostner J, Hagberg L, Kanberg N, Kanjananimmanont S, Lindh M, Misaghian S, Nilsson S, Schöll M, Sigal G, Stentoft E, Studahl M, Yilmaz A, Wang M, Stengelin M, Zetterberg H, Gisslén M.
JAMA Netw Open. 2022 May 2; 5(5).
DOI: https://doi.org/10.1001/jamanetworkopen.2022.13253
Brain charts for the human lifespan.
Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, Adler S, Alexopoulos GS, Anagnostou E, Areces-Gonzalez A, Astle DE, Auyeung B, Ayub M, Bae J, Ball G, Baron-Cohen S, Beare R, Bedford SA, Benegal V, Beyer F, Blangero J, Blesa Cábez M, Boardman JP, Borzage M, Bosch-Bayard JF, Bourke N, Calhoun VD, Chakravarty MM, Chen C, Chertavian C, Chetelat G, Chong YS, Cole JH, Corvin A, Costantino M, Courchesne E, Crivello F, Cropley VL, Crosbie J, Crossley N, Delarue M, Delorme R, Desrivieres S, Devenyi GA, Di Biase MA, Dolan R, Donald KA, Donohoe G, Dunlop K, Edwards AD, Elison JT, Ellis CT, Elman JA, Eyler L, Fair DA, Feczko E, Fletcher PC, Fonagy P, Franz CE, Galan-Garcia L, Gholipour A, Giedd J, Gilmore JH, Glahn DC, Goodyer IM, Grant PE, Groenewold NA, Gunning FM, Gur RE, Gur RC, Hammill CF, Hansson O, Hedden T, Heinz A, Henson RN, Heuer K, Hoare J, Holla B, Holmes AJ, Holt R, Huang H, Im K, Ipser J, Jack CR Jr, Jackowski AP, Jia T, Johnson KA, Jones PB, Jones DT, Kahn RS, Karlsson H, Karlsson L, Kawashima R, Kelley EA, Kern S, Kim KW, Kitzbichler MG, Kremen WS, Lalonde F, Landeau B, Lee S, Lerch J, Lewis JD, Li J, Liao W, Liston C, Lombardo MV, Lv J, Lynch C, Mallard TT, Marcelis M, Markello RD, Mathias SR, Mazoyer B, McGuire P, Meaney MJ, Mechelli A, Medic N, Misic B, Morgan SE, Mothersill D, Nigg J, Ong MQW, Ortinau C, Ossenkoppele R, Ouyang M, Palaniyappan L, Paly L, Pan PM, Pantelis C, Park MM, Paus T, Pausova Z, Paz-Linares D, Pichet Binette A, Pierce K, Qian X, Qiu J, Qiu A, Raznahan A, Rittman T, Rodrigue A, Rollins CK, Romero-Garcia R, Ronan L, Rosenberg MD, Rowitch DH, Salum GA, Satterthwaite TD, Schaare HL, Schachar RJ, Schultz AP, Schumann G, Schöll M, Sharp D, Shinohara RT, Skoog I, Smyser CD, Sperling RA, Stein DJ, Stolicyn A, Suckling J, Sullivan G, Taki Y, Thyreau B, Toro R, Traut N, Tsvetanov KA, Turk-Browne NB, Tuulari JJ, Tzourio C, Vachon-Presseau É, Valdes-Sosa MJ, Valdes-Sosa PA, Valk SL, van Amelsvoort T, Vandekar SN, Vasung L, Victoria LW, Villeneuve S, Villringer A, Vértes PE, Wagstyl K, Wang YS, Warfield SK, Warrier V, Westman E, Westwater ML, Whalley HC, Witte AV, Yang N, Yeo B, Yun H, Zalesky A, Zar HJ, Zettergren A, Zhou JH, Ziauddeen H, Zugman A, Zuo XN; 3R-BRAIN; AIBL; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Repository Without Borders Investigators; CALM Team; Cam-CAN; CCNP; COBRE; cVEDA; ENIGMA Developmental Brain Age Working Group; Developing Human Connectome Project; FinnBrain; Harvard Aging Brain Study; IMAGEN; KNE96; Mayo Clinic Study of Aging; NSPN; POND; PREVENT-AD Research Group; VETSA, Bullmore ET, Alexander-Bloch AF.
Nature. 2022 Apr 6.
DOI: https://doi.org/10.1038/s41586-022-04554-y Online ahead of print.
Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
Ann Neurol. 2022 Apr; 91(4): 548-560.
DOI: https://doi.org/10.1002/ana.26308.
Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds.
Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Simrén J, Geiger F, Zettergren A, Shams S, Machado A, Westman E, Schöll M, Skoog I, Kern S.
Alzheimers Dement. 2022 Mar 5; 14(1): e12295.
DOI: https://doi.org/10.1002/dad2.12295.
CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.
Moscoso A, Karikari TK, Grothe MJ, Ashton NJ, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M.
Alzheimers Dement. 2022 Feb 28.
DOI: https://doi.org/10.1002/alz.12570. Online ahead of print.
Comparison of Two-Dimensional- and Three-Dimensional-Based U-Net Architectures for Brain Tissue Classification in One-Dimensional Brain CT.
Srikrishna M, Heckemann RA, Pereira JB, Volpe G, Zettergren A, Kern S, Westman E, Skoog I, Schöll M.
Front. Comput. Neurosci. 2022 Jan 10.
DOI: https://doi.org/10.3389/fncom.2021.785244 Online ahead of print.
Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function.
Salami A, Adolfsson R, Andersson M, Blennow K, Lundquist A, Adolfsson AN, Schöll M, Zetterberg H, Nyberg L.
Journal of Alzheimer's Disease. 2021 Dec 16.
DOI: https://doi.org/10.3233/JAD-210673. Online ahead of print.
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances.
Chong JR, Ashton NJ, Karikari TK, Tanaka T, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP.
J Neurol Neurosurg Psychiatry. 2021 Nov; 92(11): 1231-1241.
DOI: https://doi.org/10.1136/jnnp-2021-327370.
P-tau235: a novel biomarker for staging preclinical Alzheimer's disease.
Lantero-Rodriguez J, Snellman A, Benedet AL, Milà-Alomà M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvadó G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, Suárez-Calvet M, Brinkmalm G, Rosa Neto P, Blennow K.
EMBO Mol Med. 2021 Nov 2.
DOI: https://doi.org/10.15252/emmm.202115098. Online ahead of print.
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, Shekari M, Operto G, Gispert JD, Minguillon C, Fauria K, Kollmorgen G, Suridjan I, Zimmer ER, Zetterberg H, Molinuevo JL, Paquet C, Rosa-Neto P, Blennow K, Suárez-Calvet M; Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort.
JAMA Neurol. 2021 Oct 18.
DOI: https://doi.org/10.1001/jamaneurol.2021.3671. Online ahead of print.
Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight.
Zu Eulenburg P, Buchheim JI, Ashton NJ, Vassilieva G, Blennow K, Zetterberg H, Choukér A.
JAMA Neurol. 2021 Oct 11.
DOI: https://doi.org/10.1001/jamaneurol.2021.3589. Online ahead of print.
18F-florbetapir PET as a marker of myelin integrity across the Alzheimer's disease spectrum.
Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Pías-Peleteiro JM, Ruibal Á, Aguiar P; Alzheimer’s Disease Neuroimaging Initiative.
Eur J Nucl Med Mol Imaging. 2021 Sep 28.
DOI: https://doi.org/10.1007/s00259-021-05493-y. Online ahead of print.
Microglial activation and tau propagate jointly across Braak stages.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, de Leon MJ, Soucy JP, Edison P, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P.
Nat Med. 2021 Sep; 27(9): 1592-1599.
DOI: https://doi.org/10.1038/s41591-021-01456-w.
Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT.
Srikrishna M, Pereira JB, Heckemann RA, Volpe G, van Westen D, Zettergren A, Kern S, Wahlund LO, Westman E, Skoog I, Schöll M.
Neuroimage. 2021 Sep 25.
DOI: https://doi.org/10.1016/j.neuroimage.2021.118606 Online ahead of print.
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
Milà-Alomà M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, Salvadó G, Falcon C, Gispert JD, Vilor-Tejedor N, Arenaza-Urquijo EM, Grau-Rivera O, Sala-Vila A, Sanchez-Benavides G, González-de-Echávarri JM, Minguillon C, Fauria K, Niñerola-Baizán A, Perissinotti A, Kollmorgen G, Suridjan I, Zetterberg H, Molinuevo JL, Blennow K, Suárez-Calvet M; the ALFA Study.
Neurology. 2021 Sep 23.
DOI: https://doi.org/10.1212/WNL.0000000000012853 Online ahead of print.
Current advances in digital cognitive assessment for preclinical Alzheimer’s disease.
Öhman F, Hassenstab J, Berron D, Schöll M, Papp KV.
Alzheimer's & Dementia. 2021 Jul 20.
DOI: https://doi.org/10.1002/dad2.12217 Online ahead of print.
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M; Alzheimer’s Disease Neuroimaging Initiative.
Neurology. 2021 Jul 15.
DOI: https://doi.org/10.1212/WNL.0000000000012513 Online ahead of print.
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lleó A, Parnetti L, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke J, Novakova L, Axelsson M, Velayudhan L, Rabinovici GD, Miller B, Pariante C, Nikkheslat N, Resnick SM, Thambisetty M, Schöll M, Fernández-Eulate G, Gil-Bea FJ, López de Munain A, Al-Chalabi A, Rosa-Neto P, Strydom A, Svenningsson P, Stomrud E, Santillo A, Aarsland D, van Swieten JC, Palmqvist S, Zetterberg H, Blennow K, Hye A, Hansson O.
Nature Communications. 2021 June 07;12:3400
DOI: https://doi.org/10.1038/s41467-021-23620-z.
Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.
Robert A, Schöll M, Vogels T.
Int. J. Mol. Sci. 2021 June 07;22(11):6132
DOI: https://doi.org/10.3390/ijms22116132
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y; Alzheimer’s Disease Neuroimaging Initiative, Pontecorvo MJ, Devous MD, Rabinovici GD, Alexander DC, Lyoo CH, Evans AC, Hansson O.
Nature Medicine. 2021 April 29;27:871–881
DOI: https://doi.org/10.1038/s41591-021-01309-6
Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease.
Yap SY, Frias B, Wren MC, Schöll M, Fox NC, Årstad E, Lashley T, Sander K.
Brain. 2021 March 20.
https://doi.org/10.1093/brain/awab120 Online ahead of print
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton NJ, Tharick A. Pascoal, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Schöll M, Troakes C, Hye A, Gauthier S, Vanmechelen E, Zetterberg H, Rosa-Neto P, Blennow K.
Acta Neuropathol. 2021 Feb 14;141:709–724
doi: 10.1007/s00401-021-02275-6.
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.
Salvadó G, Grothe MJ, Groot C, Moscoso A, Schöll M, Gispert JD, Ossenkoppele R.
Eur J Nucl Med Mol Imaging. 2021 Feb 1. doi: 10.1007/s00259-021-05192-8. Online ahead of print. PMID: 33521872
doi: 10.1007/s00259-021-05192-8
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D; AddNeuroMed consortium, Hansson O, Rosa-Neto P, Westman E, Blennow K, Zetterberg H, Ashton NJ.
Alzheimers Dement. 2021 Jan 25.
doi: 10.1002/alz.12283. Online ahead of print.
Pre- and postoperative 68 Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumors.
Tjörnstrand A, Casar-Borota O, Heurling K, Schöll M, Gjertsson P, Ragnarsson O, Filipsson Nyström H.
Clinical Endocrinology. 2021 Jan 23;94:956–967
doi: 10.1111/cen.14425.
Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.
Moscoso A, Grothe MJ, Schöll M.
Eur J Nucl Med Mol Imaging. 2021 Jan 21.
doi: 10.1007/s00259-021-05195-5. Online ahead of print.
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A, Suárez-Calvet M, Blennow K, Zetterberg H, Schöll M.
JAMA Neurol. 2021 Jan 11;78(4):396-406
doi: 10.1001/jamaneurol.2020.4986.
Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort.
Tanaka T, Ruifen JC, Nai YH, Tan CH, Lim CZJ, Zhang Y, Stephenson MC, Hilal S, Saridin FN, Gyanwali B, Villaraza S, Robins EG, Ihara M, Schöll M, Zetterberg H, Blennow K, Ashton NJ, Shao H, Reilhac A, Chen C.
Eur J Neurol. 2020 Dec 28;28(5):1479-1489
doi: 10.1111/ene.14704.
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Suárez-Calvet M, Zetterberg H, Blennow K, Schöll M.
Brain. 2021 Feb 12;144(1):325–339.
doi: 10.1093/brain/awaa399.
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Rosa-Neto P, Blennow K.
Brain. 2020 Dec 1;143(12):3793-3804.
doi: 10.1093/brain/awaa342.
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Moscoso A, Pascoal TA, Andreasson U, Schöll M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H; Alzheimer’s Disease Neuroimaging Initiative.
Mol Psychiatry. 2021 Feb;26(2):429–442.
doi: 10.1038/s41380-020-00923-z.
Relevance of biomarkers across different neurodegenerative.
Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, Senkevich K, Bharucha T, Jafarpour M, Young PNE, Jagust W, Carter SF, Lashley T, Grinberg LT, Pereira JB, Mattsson-Carlgren N, Ashton NJ, Hanrieder J, Zetterberg H, Schöll M, Paterson RW.
Alzheimers Res Ther. 2020 May 13;12(1):56.
DOI: 10.1186/s13195-020-00601-w PubMed
Steroid-responsive Encephalitis in Covid-19 Disease.
Pilotto A, Odolini S, Stefano Masciocchi S, Comelli A, Volonghi I, Gazzina S, Nocivelli S, Pezzini A, Focà E, Caruso A, Leonardi M, Pasolini MP, Roberto Gasparotti R, Francesco Castelli F, Ashton NJ, Blennow K, Zetterberg H, Padovani A.
Ann Neurol. 2020 Aug;88(2):423-427.
doi: 10.1002/ana.25783. PubMed
Imaging biomarkers in neurodegeneration: current and future practices.
Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, Venkataraman AV, Lissaman R, Jiménez D, Betts MJ, McGlinchey E, Berron D, O'Connor A, Fox NC, Pereira JB, Jagust W, Carter SF, Paterson RW, Schöll M.
Alzheimers Research & Therapy. 2020 Apr 27;12(1):49.
DOI: https://doi.org/10.1186/s13195-020-00612-7
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Neto PR, Blennow K.
Lancet Neurol, 2020 May;19(5):422-433.
DOI: https://doi.org/10.1016/S1474-4422(20)30071-5
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suárez-Calvet M, Karikari TK, Schöll M, La Joie R, Rabinovici GD, Höglund K, Ballard C, Hortobágyi T, Svenningsson P, Blennow K, Zetterberg H, Aarsland D.
Nat Rev Neurol. 2020 May;16(5):265-284
DOI: 10.1038/s41582-020-0348-0 PubMed
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.
Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, Mattsson N, Andreasson U, Portelius E, Ashton NJ, Blennow K, Schöll M, Paterson RW, Schott JM, Zetterberg H.
Alzheimers Research & Therapy. 2020 Feb 28;12(1):20.
DOI: 10.1186/s13195-020-00586-6. PubMed
FDG Uptake in the Basal Forebrain as Measured by Digital High-Resolution PET Is a Promising Marker of Basal Forebrain Degeneration in the Lewy Body Disease Spectrum: A Pilot Study.
Özden C, Frings L, Apostolova I, Lange C, Klutmann S, Adam G, Bannas P, Meyer PT, Grothe MJ, Buchert R.
Clin Nucl Med. 2020 Apr,45(4):261-266.
DOI: 10.1097/RLU.0000000000002960. PubMed
University College London/University of Gothenburg PhD course “Biomarkers in neurodegenerative diseases” 2019—course organization.
Khatun A, Paterson RW, Schöll M.
Alzheimer's Research & Therapy. 2020 Feb 4; 12 (1), 1-9.
DOI: 10.1186/s13195-020-0583-z PubMed
Disentangling Heterogeneity in Alzheimer's Disease and Related Dementias Using Data-Driven Methods.
Habes M, Grothe MJ, Tunc B, McMillan C, Wolk DA, Davatzikos C.
Biol Psychiatry. 2020 Jan 31; pii: S0006-3223(20)30050-0.
DOI: 10.1016/j.biopsych.2020.01.016
Lower 68Ga‐DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study.
Tjornstrand A, Casar-Borota O, Heurling K, Schöll M, Gjertsson P, Himmelman J, Itsenko O, Ragnarsson O, Filipsson Nyström H.
Clinical Endocrinology. 2020 Jan 9; 92 (3), 222-231.
DOI: 10.1111/cen.14144 PubMed
Does early cognitive decline require the presence of both tau and amyloid-β?
Schöll M & Maass A.
2020 Jan 1; Brain 143 (1), 10-13.
DOI: 10.1093/brain/awz399 PubMed
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF- Alzheimer’s Disease Multimodal Biomarker Discovery Cohort.
Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lléo A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Legido-Quigley C, Bertram L, Barkhof F, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Lovestone S.
Journal of Alzheimer's Disease, 2020 Jan 22; 1-13.
DOI: 10.3233/JAD-190434 PubMed
PET Biomarkers for Tau Pathology.
Leuzy A, Heurling K, Schöll M.
Radiopharmaceuticals, 2020; 227-234.
DOI: https://doi.org/10.1007/978-3-030-27779-6_13
An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead.
Simrén J, Ashton NJ, Blennow K, Zetterberg H.
Current Opinion in Neurobiology. 2019 Dec; 61, 29-39.
DOI: 10.1016/j.conb.2019.11.019 PubMed
Salivary biomarkers for Alzheimer’s disease and related disorders.
Ashton NJ, Ide M, Zetterberg H, Blennow K.
Neurology and Therapy. 2019 Dec 8; (2), 83-94.
DOI:10.1007/s40120-019-00168-1 PubMed
Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial.
Rosqvist F, Kullberg J, Ståhlman M, Cedernaes J, Heurling K, Johansson HE, Iggman D, Wilking H, Larsson A, Eriksson O, Johansson L, Straniero S, Rudling M, Antoni G, Lubberink M, Orho-Melander M, Borén J, Ahlström H, Risérus U.
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6207-6219.
DOI: 10.1210/jc.2019-00160. PubMed
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H.
Alzheimers Res Ther. 2019 Nov 28;11(1):94.
DOI: 10.1186/s13195-019-0545-5. PubMed
Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, Hye A, Pedrini S, Sohrabi HR, Shah T, Asih PR, Dave P, Shen K, Taddei K, Lovejoy DB, Guillemin GJ, Blennow K, Martins RN.
J Neuroinflammation. 2019 Oct 10;16(1):186.
DOI: 10.1186/s12974-019-1567-4. PubMed
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM, Ashton NJ, Hamburg S, Hithersay R, Wiseman FK, Mok KY, Hardy J, Lleó A, Lovestone S, Parnetti L, Zetterberg H, Hye A; LonDownS Consortium, Strydom A.
Alzheimers Res Ther. 2019 Mar 21;11(1):26.
DOI: 10.1186/s13195-019-0477-0. PubMed
Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.
Benedet AL*, Ashton NJ*, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, Therriault J, Savard M, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Blennow K, Neto PR.
Alzheimers Dement (Amst). 2019 Sep 27;11:679-689.
DOI: 10.1016/j.dadm.2019.08.002. eCollection 2019 Dec. PubMed
A walk through tau therapeutic strategies.
Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N.
Acta neuropathol commun, 2019 Feb 15; 7, 22
DOI:10.1186/s40478-019-0664-z. PubMed
Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.
Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M.
J Cereb Blood Flow Metab. 2019 Nov; 39(11):2223-2232.
DOI: 10.1177/0271678X18791430. PubMed
Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
Thal DR, Ronisz A, Tousseyn T, Rijal Upadhaya A, Balakrishnan K, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Otto M, Beach TG, Lilja J, Heurling K, Chakrabarty A, Ismail A, Buckley C, Smith APL, Kumar S, Farrar G, Walter J.
Acta Neuropathol Commun. 2019 Nov 14;7(1):178.
DOI: 10.1186/s40478-019-0837-9. PubMed
Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum.
Rajan, MR, Sotak, M, Barrenäs F, Shen T, Borkowski K, Ashton NJ, Biörserud C, Lindahl TL, Ramström S, Schöll M, Lindahl P, Fiehn O, Newman JW, Perkins R, Wallenius V, Lange S, Börgenson E.
Sci Rep, 2019 Oct 28; 9, 15385
DOI:10.1038/s41598-019-51673-0. PubMed
A Deep Learning Approach to MR-less Spatial Normalization for Tau PET Images. (2019).
Alvén J, Heurling K, Smith R, Strandberg O, Schöll M, Hansson O, Kahl F, In: Shen D. et al. (eds) Medical Image Computing and Computer Assisted Intervention – MICCAI 2019. MICCAI 2019. Lecture Notes in Computer Science, vol 11765. Springer, Cham
DOI: 10.1007/978-3-030-32245-8_40
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.
Smith R, Schöll M, Leuzy A, Jögi J, Ohlsson T, Strandberg O, Hansson O.
Eur J Nucl Med Mol Imaging. 2019 Oct 14; 1-13.
DOI: 10.1007/s00259-019-04496-0. PubMed
Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies.
Vogels T, Leuzy A, Cicognola C, Ashton NJ, Smolek T, Novak M, Blennow K, Zetterberg H, Hromadka T, Zilka N, Schöll M.
Biol Psychiatry. 2019 Oct 3. pii: S0006-3223(19)31744-5.
DOI: 10.1016/j.biopsych.2019.09.019. PubMed
Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset.
Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB.
Alzheimer’s Disease Neuroimaging Initiative, Journal of Neurology, 2019 Oct 1; 266 (10), 2535-2545.
DOI: 10.1007/s00415-019-09441-7. PubMed
Predicting MCI Status From Multimodal Language Data Using Cascaded Classifiers
Fraser KC, Lundholm Fors K, Eckerström M, Öhman F, Kokkinakis D.
Front. Aging Neurosci., 02 August 2019
DOI: 10.3389/fnagi.2019.00205 Pubmed
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.
Heurling K, Ashton NJ, Leuzy A, Zimmer ER, Blennow K, Zetterberg H, Eriksson J, Lubberink M, Schöll M.
Mol Cell Neurosci. 2019 Jun;97:34-42.
DOI: 10.1016/j.mcn.2019.02.001. PubMed
Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies.
Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA;
AMYPAD Consortium. EJNMMI Res. 2019 Mar 27;9(1):32.
DOI: 10.1186/s13550-019-0499-4. PubMed
A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.
Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.
Sci Adv. 2019 Feb 6;5(2):eaau7220.
DOI: 10.1126/sciadv.aau7220. eCollection 2019 Feb PubMed
Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.
Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R;
Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study. Hum Brain Mapp. 2019 Feb 1;40(2):638-651
DOI: 10.1002/hbm.24401. PubMed
Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease.
Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O.
Alzheimers Dement. 2019 Jan 24. pii: S1552-5260(18)33605-7.
DOI: 10.1016/j.jalz.2018.12.001. PubMed
Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.
Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A.
Acta Neuropathol Commun. 2019 Jan 9;7(1):5.
DOI: 10.1186/s40478-018-0649-3. PubMed
Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result.
Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, Galimberti D, Parnetti L, Lleó A, Baker S, Narayan VA, van der Flier WM, Scheltens P, Teunissen CE, Visser PJ, Lovestone S.
Front Aging Neurosci. 2018 Dec 11;10:409.
DOI: 10.3389/fnagi.2018.00409. PubMed
Biomarkers for tau pathology.
Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W.
Mol Cell Neurosci. 2018 Dec 7. pii: S1044-7431(18)30233-1
DOI: 10.1016/j.mcn.2018.12.001. PubMed
Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.
Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O.
Neurobiol Aging. 2018 Nov;71:81-90.
DOI: 10.1016/j.neurobiolaging.2018.07.003. PubMed
Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.
Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, Ismail A, Farrar G, Buckley C, Smith APL.
Acta Neuropathol. 2018 Oct;136(4):557-567.
DOI: 10.1007/s00401-018-1897-9. PubMed
Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
Gonzales MM, Insel PS, Nelson C, Tosun D, Schöll M, Mattsson N, Sacuiu S, Bickford D, Weiner MW, Mackin RS;
Alzheimer's Disease Neuroimaging Initiative. Int J Geriatr Psychiatry. 2018 Oct;33(10):1305-1311.
DOI: 10.1002/gps.4926. PubMed
No association of salivary total tau concentration with Alzheimer's disease.
Ashton NJ, Ide M, Schöll M, Blennow K, Lovestone S, Hye A, Zetterberg H.
Neurobiol Aging. 2018 Oct;70:125-127.
DOI: 10.1016/j.neurobiolaging.2018.06.014. PubMed
In vivo Detection of Alzheimer's Disease.
Leuzy A, Heurling K, Ashton NJ, Schöll M, Zimmer ER.
Yale J Biol Med. 2018 Sep 21;91(3):291-300
PMCID: PMC6153625 PubMed
Discriminative accuracy of [18f] flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders.
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.
JAMA. 2018 Sep 18;320(11):1151-1162.
DOI: 10.1001/jama.2018.12917. PubMed
Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ;
Alzheimer’s Disease Neuroimaging Initiative. Brain. 2018 Sep 1;141(9):2755-2771
DOI: 10.1093/brain/awy189. PubMed
Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study.
Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW.
Horm Metab Res. 2018 Aug;50(8):627-639
DOI: 10.1055/a-0831-3620. PubMed
Update on biomarkers for amyloid pathology in Alzheimer's disease.
Ashton NJ, Schöll M, Heurling K, Gkanatsiou E, Portelius E, Höglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H.
Biomark Med. 2018 Jul;12(7):799-812.
DOI: 10.2217/bmm-2017-0433. PubMed
Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.
Thordardottir S, Rodriguez-Vieitez E, Almkvist O, Ferreira D, Saint-Aubert L, Kinhult-Ståhlbom A, Thonberg H, Schöll M, Westman E, Wall A, Eriksdotter M, Zetterberg H, Blennow K, Nordberg A, Graff C.
Alzheimer's research therapy, 2018 May 10; 10(1):45
DOI: 10.1186/s13195-018-0374-y PubMed
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies.
Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.
Sci Rep, 2018 Mar 16, 8, 4717
DOI:10.1038/s41598-018-23041-x PubMed
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.
Palmqvist S*, Schöll M*, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. *contributed equally.
Nature Communications. 2017 Oct 31;8(1):1214.
DOI: 10.1038/s41467-017-01150-x. PubMed
Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease.
Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S; Swedish BioFINDER study, Jögi J, Ohlsson T, Smith R, Hansson O.
Brain. 2017 Sep 1;140(9):2286-2294.
DOI: 10.1093/brain/awx171 PubMed
Quantitative positron emission tomography in brain research.
Heurling K, Leuzy A, Jonasson M, Frick A, Zimmer ER, Nordberg A, Lubberink M.
Brain Res. 2017 Sep 1;1670:220-234.
doi: 10.1016/j.brainres.2017.06.022. PubMed
In vivo retention of 18F-AV-1451 in corticobasal syndrome.
Smith R, Schöll M, Widner H, Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.
Neurology. 2017 Aug 22, 89 (8) 845-853;
DOI:10.1212/WNL.0000000000004264 PubMed
Linking Amyloid-β and Tau Deposition in Alzheimer Disease.
Vemuri P, Schöll M.
JAMA Neurol.2017 Jul 1;74(7):766–768.
DOI: 10.1001/jamaneurol.2017.0323 PubMed
